

# DEWS Disclosures

## Disclosures of financial/proprietary relationships of DEWS participants with companies with products or interests related to dry eye

### STEERING COMMITTEE MEMBERS

**Christophe Baudouin** has received financial support from Alcon, Allergan, Pfizer, Santen, and Thea. He has been a consultant to Alcon, Allergan, Bausch & Lomb, Novagali, Pfizer, Santen, and Laboratoires Théa and is currently consulting for Allergan, Novartis, Pfizer and Novagali.

**Anthony J. Bron** has a personal financial interest in OcuSense. He has been a consultant to Acucela, Alcon, Novartis, OcuSense, Proctor and Gamble, Senju, and Takeda, and he has received gifts from Alcon, Allergan, and Takeda. Currently, Professor Bron is a consultant for Actelion, Acucela, Canfite Novagali, OcuSense, Proctor and Gamble and Takeda. He receives meeting support from Alcon, and Allergan.

**Murat Dogru** has no proprietary interest in any company with products or interests related to dry eye.

**Gary N. Foulks** has received financial support from Alacrity, Allergan, Inspire, Lantibio, Novartis, and Otsuka and he has a personal financial interest in Inspire. He is, or has been, a consultant to Alacrity, Alcon, Alimera Sciences, Allergan, Bausch & Lomb, Fovea, Inspire, ISTA, Lantibio, Nascent, Novagali, Novartis, OcuSense, Otsuka, and Pfizer, Santen, Sarcode and XTL Biopharmaceuticals. He has received gifts from Alacrity, Alcon, Bausch & Lomb, Inspire, Otsuka, and Pfizer.

**Ilene K. Gipson** has received financial support from Alcon.

**Michael A. Lemp** has received financial support from Addition Technologies, Alcon, Allergan, Bausch & Lomb, Inspire, Novagali, Novartis, Pfizer, OcuSense, and Santen. He is a consultant for Otsuka Research Corp. and Fovea Pharmaceuticals. He has a personal financial interest in Inspire and OcuSense, and he is Chief Medical Officer of OcuSense.

**J. Daniel Nelson** has no proprietary interest in any company with products or interests related to dry eye. He is listed on a patent for dry eye that is held by the University of Illinois.

**Kelly K. Nichols** has a personal financial interest in Inspire, and she is a consultant to Alcon, Allergan, and Inspire.

**Stephen C. Pflugfelder** has received support from Allergan, and he is a consultant to Allergan. He is listed on two patents held by the University of Miami that relate to dry eye disease.

**Debra A. Schaumberg** has received financial support from DSM Pharmaceuticals, Daiichi, and Pfizer Consumer Healthcare, Inc. She has a personal financial interest in OcuSense, and she is a consultant to OcuSense.

**Janine A. Smith** is named on a patent held by the US government.

**David A. Sullivan** has received financial support from Allergan, and has served as a consultant to Allergan and Novartis. He is named as the inventor on patents for Sjogren Syndrome and Keratoconjunctivitis Sicca treatments held by the Schepens Eye Research Institute.

**Alan Tomlinson** has received financial support from Allergan, Renaissance Pharmaceuticals, and Pfizer. He has a personal financial interest in Bausch & Lomb.

**Kazuo Tsubota** has received financial support from Etech and Santen, and he is a consultant to Nidek and Rainbow. He is named on multiple patents both in the U.S. and Japan that relate to dry eye disease.

### SUBCOMMITTEE MEMBERS

**Mark Abelson** is president of Ophthalmic Research Associates, a company that provides consulting and research services to many ophthalmic industries.

**Julie Albietz** has no proprietary interest in any company with products or interests related to dry eye.

**Pablo Argüeso** has received financial support from Alcon.

**Penny Asbell** serves as a Speaker Bureau consultant to Alcon, Allergan, Bausch & Lomb, Inspire, Novagali, Novartis, Otsuka, Pfizer, Santen, and Vistakon Pharma.

**Jules Baum** has no proprietary interest in any company with products or interests related to dry eye.

**Carolyn Begley** has received financial support from Alcon Research, Allergan, and Vistakon. She is a consultant to Alcon and Novartis.

**Roger Beuerman** has received financial support from Advanced Ocular Systems and Allergan, and he is a consultant to both companies.

**Stefano Bonini** has received financial support from Alcon, Allergan, Bausch & Lomb, Novartis, SIFI and SOOFT. He is a member of the Anabasis Society, SrL, which holds rights to a patent for the use of NGF as it relates to the treatment dry eye disease.

**Igor Butovich** has no proprietary interest in any company with products or interests related to dry eye.

**Barbara Caffery** has no proprietary interest in any company with products or interests related to dry eye.

**Margarita Calonge** is a consultant to Allergan.

**Reza Dana** has received financial support from Allergan, Biogen-Idec, and Johnson & Johnson. He is a consultant to Johnson & Johnson.

**Darlene Dartt** has received financial support from Johnson & Johnson and Otsuka. She is a consultant to Johnson & Johnson, and holds a patent with that company. She has received gifts from Johnson & Johnson and Alcon.

**Desmond Fonn** has received financial support from Advanced Medical Optics, Alcon, Allergan, Bausch & Lomb, Ciba Vision, CooperVision, and Johnson & Johnson Vision Care. He is a consultant to Ciba Vision, and he has received gifts from Ciba Vision and CooperVision.

**Daniel Gamache** is employed by Alcon and is named on many of its patents related to dry eye disease.

**Gerd Geerling** is a consultant to Pfizer Health

Care and Novartis Pharma. He holds a patent application for a dry eye product. The patent has not been assigned.

**Eiki Goto** has no proprietary interest in any company with products or interests related to dry eye.

**Franz Grus** has no proprietary interest in any company with products or interests related to dry eye.

**Bryan Ham** has no proprietary interest in any company with products or interests related to dry eye.

**Marcia Jumblatt** has no proprietary interest in any company with products or interests related to dry eye.

**Shigeru Kinoshita** has received financial support from Alcon Japan, Alblast Ltd, Otsuka, Senju, and Santen. He is a consultant to Advanced Medical Optics, Otsuka and Senju.

**Donald Korb** has a personal financial interest in Ocular Research of Boston and Kolis Scientific. He is an employee of and holds patents with both companies.

**Friedrich Kruse** has no proprietary interest in any company with products or interests related to dry eye.

**Peter Laibson** has no proprietary interest in any company with products or interests related to dry eye. He is on the Speakers Bureau for Bausch & Lomb.

**James McCulley** is a consultant for Alcon Laboratories.

**Juan Murube** has no proprietary interest in any company with products or interests related to dry eye disease.

**Gary Novack** owns and operates PharmaLogic, which provides editorial and consulting services to industry.

**George Ousler** is employed by Ophthalmic Research Associates, a company that provides consulting and research services to many ophthalmic industries.

**Jerry Paugh's** employing institution has received financial support from Alcon, Allergan, and Bausch & Lomb.

**Friedrich Paulsen** has no proprietary interest in any company with products or interests related to dry eye.

**Ian E. Pearce** has received support from Allergan, Pfizer, and Sequani, Ltd. He is a consultant to Pfizer, and he has received gifts from Pfizer.

**Maurizio Rolando** has received gifts from Alcon and Pfizer.

**Oliver Schein** has received financial support from Bausch & Lomb, Novartis, and he has received financial support from CIBA (inactive). He is a consultant to Bausch & Lomb.

**Jun Shimazaki** has no proprietary interest in any company with products or interests related to dry eye.

**Michael Stern** is employed by Allergan.

*continued on page 204*



## DEWS DISCLOSURES *continued*

**Deborah Sweeney** has no proprietary interest in any company with products or interests related to dry eye.

**John Tiffany** is a consultant to Pfizer Consumer Healthcare. He holds a patent for lipid-containing eyedrops (no longer active).

**Ikuko Toda** has no proprietary interest in any company with products or interests related to dry eye.

**John Ubels** has no proprietary interest in any company with products or interests related to dry eye. He is a consultant for Alcon Research, Ltd.

**Hitoshi Watanabe** has no proprietary interest in any company with products or interests related to dry eye.

**Mark Willcox** has received financial support from CIBA, Alcon, Allergan, Clearlab International Pte, and Ocular Sciences (CooperVision). He currently receives funding from Alcon, Allergan, Bausch & Lomb, and CIBA Vision.

**Clive G. Wilson** has received financial support from industries in the fields of gastroenterology and ocular drug delivery unrelated to dry eye. He is a consultant to Allergan (retinal drug delivery) and to GlaxoSmithKline (biopharmaceutics).

**Norihiko Yokoi** has no proprietary interest in any company with products or interests related to dry eye.

### INDUSTRY LIAISON COMMITTEE

**Fouad Amer** is employed by Novartis.

**Michael J. Brubaker** is employed by Alcon.

**Timothy Comstock** is employed by Bausch & Lomb.

**David Eveleth** is employed by Pfizer.

**William Florida** formerly employed by Novartis.

**Fulvio Foschini** is employed by SOOFT.

**Sherryl Frisch** formerly employed by Pfizer, now Johnson & Johnson, McNeil Consumer Health Care Group

**Jeff Gilbard** is employed by Advanced Vision Research and is a consultant to that company.

**Kate Kline** is employed by Allergan.

**Ami Shah** formerly of Bausch & Lomb

**Masatsugu Nakamura** is employed by Santen.

**Ian Vessey** is employed by Novartis.

### NON-MEMBER ATTENDEES

**Piero Biondi** is employed by SOOFT.

**Elizabeth Fini** is employed by Bascom-Palmer Eye Institute.

**Sebastiano Giuffrida** is employed by Bausch & Lomb.

**Marco Marchetti** is employed by SOOFT.

**Becky Palchek** is employed by Santen.

**Christopher Paterson** is employed by the University of Louisville.

**Kevin Stanley** formerly of Alcon Laboratories.